A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Phase of Trial: Phase III
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Ubrogepant (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- Acronyms ACHIEVE II
- Sponsors Allergan
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 06 Feb 2018 According to an Allergan media release, results from this trial are expected in the first half of 2018.
- 05 Jan 2018 Planned End Date changed from 14 Dec 2017 to 26 Mar 2018.